Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
P/E ratio for Innoviva, Inc. (INVA)
P/E ratio as of 2023: 5.84
According to Innoviva, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 5.84. At the end of 2022 the company had a P/E ratio of 4.31.
P/E ratio history for Innoviva, Inc. from 2000 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 5.84 |
| 2022 | 4.31 |
| 2021 | 3.84 |
| 2020 | 5.59 |
| 2019 | 9.11 |
| 2018 | 4.45 |
| 2017 | 11.31 |
| 2016 | 19.82 |
| 2015 | -64.82 |
| 2014 | -9.00 |
| 2013 | -16.02 |
| 2012 | -81.66 |
| 2011 | -11.77 |
| 2010 | -16.14 |
| 2009 | -7.23 |
| 2008 | -6.08 |
| 2007 | -5.52 |
| 2006 | -8.22 |
| 2005 | -6.28 |
| 2004 | -4.35 |
| 2003 | -1.31 |
| 2002 | -1.08 |
| 2001 | -1.16 |
| 2000 | -0.54 |